Divi's Laboratories, a Rs.2,130 crore plus Hyderabad based active pharmaceuticals ingredients and intermediates manufacturer, has suffered setback during the fourth quarter ended March 2013 on account of higher power charges and lower sales. The consolidated net profit declined by 16.8 per cent to Rs.180.57 crore during the fourth quarter from Rs.216.91 crore in the corresponding period of last year. Its net sales also declined by 8.7 per cent to Rs.655.83 crore from Rs.718.04 crore. The EBDITA moved down by 11.5 per cent to Rs.257.79 crore from Rs.291.04 crore.

Despite lower profit, the board of directors has recommended hansom equity dividend of 750 per cent (Rs.15 per share of Rs.2 each) for the year ended March 2013. The company received major setback due to severe power shortage in the State of Andhra Pradesh. Further it incurred a forex loss of Rs.7.78 crore during the quarter. Exports constituted 90 per cent of sales and bout 76 per cent to advanced markets in North America and Europe.

For the full year ended March 2013, Divi's consolidated net sales increased by 15.2 per cent to Rs.2,140 crore from Rs.1,858 crore in the previous year. Its EBDITA moved up by 15.2 per cent to Rs.860 crore from Rs.746 crore and net profit by 12.9 per cent to Rs.602 crore from Rs.533 crore. Its employees cost went up by 31 per cent to Rs.198 crore from Rs.151 crore. The company is paying negligible interest cost of Rs.1.78 crore as compared to Rs.3.74 crore in the previous year.

Earnings per share for the full year worked out to Rs.45.35 as compared to Rs.40.19 in the previous year. As against the equity capital of Rs.26.55 crore, its reserves and surplus amounted to Rs.2,474 crore as against Rs.2,105 crore.